CGH
NTLA icon

Contrarius Group Holdings’s Intellia Therapeutics NTLA Stock Holding History

Contrarius Group Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1M Buy
1,955,228
+43,389
+2% +$607K 1.52% 16
2026
Q1 		$24.5M Buy
1,911,839
+1,197,359
+168% +$15.3M 1.39% 16
2025
Q4 		$6.42M Sell
714,480
-5,175,456
-88% -$71.2M 0.31% 42
2025
Q3 		$102M Buy
5,889,936
+4,337,428
+279% +$53.4M 4.6% 6
2025
Q2 		$14.6M Sell
1,552,508
-468,532
-23% -$3.85M 0.82% 21
2025
Q1 		$14.4M Buy
2,021,040
+1,009,177
+100% +$10.2M 0.98% 21
2024
Q4 		$11.8M Buy
+1,011,863
New +$15.8M 0.72% 25

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Contrarius Group Holdings's NTLA Position: Q2 2026 in Review

Contrarius Group Holdings increased its Intellia Therapeutics (NTLA) stake by 2.3% in Q2 2026, buying an estimated $607K and bringing the position to 1,955,228 shares worth $33.1M. The position accounts for 1.52% of the portfolio, ranked #16.

Contrarius Group Holdings first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $102M in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Contrarius Group Holdings held 1,955,228 shares of Intellia Therapeutics worth $33.1M as of Q2 2026.
  • Contrarius Group Holdings bought 43,389 Intellia Therapeutics shares in Q2 2026, an estimated $607K.
  • Intellia Therapeutics made up 1.52% of Contrarius Group Holdings's portfolio in Q2 2026, its #16 holding.
  • Contrarius Group Holdings first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Contrarius Group Holdings's Intellia Therapeutics position peaked at $102M in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Contrarius Group Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.